DDInter1042 DDInter1851
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of antidepressants. It is used in adults and has been shown to be comparable in efficacy to other drugs such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine receptor inhibitor (SNRIs) in the treatment of depression. A unique feature of this drug is that it does not promote the anxiety symptoms, sexual symptoms, or insomnia, which are commonly associated with SSRI and SNRI therapy. Trazodone acts on various receptors, including certain histamine, serotonin, and adrenergic receptors, distinguishing it from other antidepressants that cover a narrow range of neurotransmitters. It was initially granted FDA approval in 1981.
Trazodone {u} (Compound) resembles {v} (Compound) Zuclopenthixol
Trazodone {u} (Compound) resembles {v} (Compound) Quetiapine
Trazodone {u} (Compound) binds {v} (Gene) HTR2C
Trazodone {u} (Compound) palliates {v} (Disease) bipolar disorder
Trazodone {u} (Compound) downregulates {v} (Gene) PIN1
Trazodone {u} (Compound) causes {v} (Side Effect) Tachycardia
Trazodone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Trazodone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Levothyroxine
Trazodone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Salbutamol
Trazodone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Quinine
Trazodone (Compound) resembles Zuclopenthixol (Compound)
Trazodone (Compound) resembles Quetiapine (Compound)
Trazodone (Compound) binds HTR2C (Gene)
Trazodone (Compound) palliates bipolar disorder (Disease)
Trazodone (Compound) downregulates PIN1 (Gene)
Trazodone (Compound) causes Tachycardia (Side Effect)
Trazodone may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Trazodone may cause a minor interaction that can limit clinical effects when taken with Levothyroxine
Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Quinine